Your browser doesn't support javascript.
loading
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth.
Dimopoulos, Meletios A; Lonial, Sagar; White, Darrell; Moreau, Philippe; Palumbo, Antonio; San-Miguel, Jesus; Shpilberg, Ofer; Anderson, Kenneth; Grosicki, Sebastian; Spicka, Ivan; Walter-Croneck, Adam; Magen, Hila; Mateos, Maria-Victoria; Belch, Andrew; Reece, Donna; Beksac, Meral; Bleickardt, Eric; Poulart, Valerie; Sheng, Jennifer; Sy, Oumar; Katz, Jessica; Singhal, Anil; Richardson, Paul.
Afiliação
  • Dimopoulos MA; Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
  • Lonial S; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.
  • White D; Division of Hematology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada.
  • Moreau P; Department of Haematology, University Hospital, Nantes, France.
  • Palumbo A; Myeloma Unit, Division of Haematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.
  • San-Miguel J; Clinica Universidad de Navarra, Investigación Médica Aplicada, IDISNA, CIBERONC, Pamplona, Spain.
  • Shpilberg O; Institute of Haematology, Assuta Medical Centers, Tel Aviv, Israel.
  • Anderson K; Division of Hematologic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Grosicki S; Department of Cancer Prevention, Medical University of Silesia, Katowice, Poland.
  • Spicka I; 1st Department of Medicine - Department of Haematology, First Faculty of Medicine, Charles University and General Teaching Hospital in Prague, Prague, Czech Republic.
  • Walter-Croneck A; Department of Haemato-oncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland.
  • Magen H; Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel.
  • Mateos MV; Haematology Department, University Hospital of Salamanca-Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain.
  • Belch A; Department of Oncology, Cross Cancer Institute and University of Alberta, Edmonton, AB, Canada.
  • Reece D; Department of Medical Oncology and Haematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Beksac M; Department of Haematology, Ankara University, Ankara, Turkey.
  • Bleickardt E; Oncology Clinical Development, Bristol-Myers Squibb, Lawrenceville, NJ, USA.
  • Poulart V; Global Biostatistics, Bristol-Myers Squibb, Lawrenceville, NJ, USA.
  • Sheng J; Clinical Pharmacology & Pharmacometrics, Bristol-Myers Squibb, Lawrenceville, NJ, USA.
  • Sy O; Global Biometric Sciences, Bristol-Myers Squibb, Lawrenceville, NJ, USA.
  • Katz J; Global Clinical Research (Research and Development Oncology), Bristol-Myers Squibb, Lawrenceville, NJ, USA.
  • Singhal A; AbbVie Biotherapeutics Inc. (ABR), Redwood City, CA, USA.
  • Richardson P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Br J Haematol ; 178(6): 896-905, 2017 Sep.
Article em En | MEDLINE | ID: mdl-28677826
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Mieloma Múltiplo Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Mieloma Múltiplo Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article